Lexeo Therapeutics, Inc. (NASDAQ:LXEO – Free Report) – Equities researchers at Leerink Partnrs reduced their FY2024 EPS estimates for shares of Lexeo Therapeutics in a research note issued on Wednesday, November 13th. Leerink Partnrs analyst M. Foroohar now forecasts that the company will earn ($3.04) per share for the year, down from their prior forecast of ($2.65). The consensus estimate for Lexeo Therapeutics’ current full-year earnings is ($3.05) per share. Leerink Partnrs also issued estimates for Lexeo Therapeutics’ Q4 2024 earnings at ($0.73) EPS, FY2025 earnings at ($3.00) EPS, FY2026 earnings at ($2.55) EPS and FY2027 earnings at ($2.51) EPS.
A number of other equities analysts have also issued reports on the stock. Royal Bank of Canada reiterated an “outperform” rating and issued a $24.00 target price on shares of Lexeo Therapeutics in a research report on Tuesday, August 13th. Leerink Partners decreased their target price on shares of Lexeo Therapeutics from $20.00 to $19.00 and set an “outperform” rating for the company in a research report on Wednesday, November 13th. HC Wainwright upped their price target on shares of Lexeo Therapeutics from $21.00 to $23.00 and gave the company a “buy” rating in a report on Thursday. Finally, Chardan Capital upped their price target on shares of Lexeo Therapeutics from $23.00 to $25.00 and gave the company a “buy” rating in a report on Wednesday, November 13th. Eight research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $22.71.
Lexeo Therapeutics Stock Performance
Shares of LXEO opened at $6.65 on Monday. The firm has a 50-day moving average price of $9.01 and a 200 day moving average price of $12.23. The firm has a market capitalization of $219.92 million and a PE ratio of -2.10. The company has a quick ratio of 9.38, a current ratio of 5.95 and a debt-to-equity ratio of 0.01. Lexeo Therapeutics has a 52-week low of $6.65 and a 52-week high of $22.33.
Insider Buying and Selling at Lexeo Therapeutics
In other news, CEO Richard Nolan Townsend sold 5,000 shares of the stock in a transaction that occurred on Thursday, October 10th. The shares were sold at an average price of $8.10, for a total value of $40,500.00. Following the completion of the sale, the chief executive officer now directly owns 120,695 shares of the company’s stock, valued at $977,629.50. This represents a 3.98 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Over the last ninety days, insiders sold 12,500 shares of company stock valued at $113,300. 4.50% of the stock is currently owned by corporate insiders.
Hedge Funds Weigh In On Lexeo Therapeutics
A number of hedge funds have recently added to or reduced their stakes in the company. Janus Henderson Group PLC increased its holdings in Lexeo Therapeutics by 18.9% in the third quarter. Janus Henderson Group PLC now owns 3,763,195 shares of the company’s stock worth $33,997,000 after buying an additional 599,203 shares during the last quarter. Frazier Life Sciences Management L.P. acquired a new position in Lexeo Therapeutics in the third quarter worth approximately $11,307,000. Vestal Point Capital LP increased its holdings in Lexeo Therapeutics by 1.2% in the third quarter. Vestal Point Capital LP now owns 850,000 shares of the company’s stock worth $7,684,000 after buying an additional 10,000 shares during the last quarter. Artal Group S.A. increased its holdings in Lexeo Therapeutics by 32.9% in the first quarter. Artal Group S.A. now owns 801,716 shares of the company’s stock worth $12,571,000 after buying an additional 198,281 shares during the last quarter. Finally, Verition Fund Management LLC increased its holdings in Lexeo Therapeutics by 84.5% in the third quarter. Verition Fund Management LLC now owns 777,320 shares of the company’s stock worth $7,027,000 after buying an additional 355,928 shares during the last quarter. Institutional investors and hedge funds own 60.67% of the company’s stock.
Lexeo Therapeutics Company Profile
Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.
See Also
- Five stocks we like better than Lexeo Therapeutics
- How to Find Undervalued Stocks
- Warren Buffett, Cathie Wood Own Nu Holdings, Should You?
- Are Penny Stocks a Good Fit for Your Portfolio?
- MercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?
- Options Trading – Understanding Strike Price
- ORIC: Working with Two Pharma Giants, Analysts See +100% Upside
Receive News & Ratings for Lexeo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexeo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.